VITAE PHARMACEUTICALS
Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets with significant unmet medical needs, including chronic kidney disease, diabetes, atherosclerosis and Alzheimer's disease.
VITAE PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Test And Measurement
Founded:
2001-01-01
Address:
Fort Washington, Pennsylvania, United States
Country:
United States
Website Url:
http://www.vitaepharma.com
Total Employee:
51+
Status:
Active
Contact:
2154612016
Email Addresses:
[email protected]
Total Funding:
94 M USD
Technology used in webpage:
Domain Not Resolving SPF IPv6 Akamai EdgeConnect
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Prospect Venture Partners
Prospect Venture Partners investment in Series D - Vitae Pharmaceuticals
Atlas Venture
Atlas Venture investment in Series D - Vitae Pharmaceuticals
Venrock
Venrock investment in Series D - Vitae Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series D - Vitae Pharmaceuticals
Venrock
Venrock investment in Series C - Vitae Pharmaceuticals
Atlas Venture
Atlas Venture investment in Series C - Vitae Pharmaceuticals
Wellcome Trust
Wellcome Trust investment in Series C - Vitae Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series C - Vitae Pharmaceuticals
Prospect Venture Partners
Prospect Venture Partners investment in Series C - Vitae Pharmaceuticals
Venrock
Venrock investment in Series B - Vitae Pharmaceuticals
Official Site Inspections
http://www.vitaepharma.com
- Host name: 159.180.132.176
- IP address: 159.180.132.176
- Location: North Chicago United States
- Latitude: 42.325
- Longitude: -87.8561
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60064
More informations about "Vitae Pharmaceuticals"
Vitae Pharmaceuticals - PitchBook
Operator of a clinical-stage biopharmaceutical company focused on discovery of drugs for diseases with significant unmet medical needs. The company develops novel, small-molecule …See details»
Vitae Pharmaceuticals - Crunchbase Company Profile …
Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets with significant unmet medical needs, including chronic kidney …See details»
Vitae Pharmaceuticals - Products, Competitors, Financials, …
Vitae Pharmaceuticals (NASDAQ: VTAE) operates as a clinical-stage biopharmaceutical company. It discovers and develops a portfolio of small molecule compounds that address …See details»
Vitae Pharmaceuticals - LinkedIn
We need to have people know what we do, and why we became medicinal chemists; we need to engage the general public. We need to have our stories heard. Chemists Invent Drugs and …See details»
Allergan to Acquire Vitae Pharmaceuticals Adding Innovative …
Sep 14, 2016 · Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is …See details»
Vitae Pharmaceuticals - Company Profile & Staff Directory
Vitae Pharmaceuticals is a clinical stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large market opportunities, including …See details»
Vitae Pharmaceuticals - VentureRadar
Website: http://www.vitaepharma.com. Vitae Pharmaceuticals is leveraging a proprietary drug discovery platform to develop therapies in cardiovascular, neurological and metabolic …See details»
Vitae Pharmaceuticals, Inc. Hires Tina Fiumenero As Senior
Feb 16, 2006 · Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated to the discovery and development of innovative drugs by advancing its pipeline of product candidates.See details»
Allergan signs agreement to acquire Vitae Pharmaceuticals for …
Sep 14, 2016 · Allergan has entered into a definitive agreement to acquire Vitae Pharmaceuticals, a clinical-stage biotechnology company, for approximately $639m. The boards of directors of …See details»
EX-99.3 - SEC.gov
Acquisition of Vitae Pharmaceuticals, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases with significant unmet …See details»
Allergan is now part of AbbVie
We offer over 30+ brands treating 60+ conditions from oncology and immunology to aesthetics and eye care. Search our global list of products or filter by therapeutic area. With a single …See details»
Vitae Pharmaceuticals Receives $14 Million Milestone Payment as ...
Jun 29, 2010 · FORT WASHINGTON, Pa.-- (BUSINESS WIRE)-- Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 …See details»
Vitae Pharmaceuticals Announces Initiation of a Phase 1
Jun 29, 2015 · Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing first-in-class, small molecule drugs for difficult-to-drug disease …See details»
Vitae Pharmaceuticals Announces Positive Top-Line Results
FORT WASHINGTON, Pa., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today reported positive top-line …See details»
Vitae Achieves Proof-of-Concept with First-in-Class RORyt …
Mar 17, 2016 · VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including psoriasis, …See details»
Vitae Pharmaceuticals Announces Positive Top-Line Results From a …
Nov 18, 2015 · cbc359bd3c0c98d33a810f3b265b28.fY8ezU83gb1CwEP2Wj_oelFhWJb6mvS84zZ5xN0xz5A.TLwphg1etc12oybCLw6hGQc2CKWy2Jj5lH4hq4RSpftE9Vr4LnLN1y6lcw …See details»
Vitae Pharmaceuticals, Inc. Initiates Phase II Clinical ... - BioSpace
Nov 29, 2005 · Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated to the discovery and development of innovative drugs by advancing its pipeline of product candidates.See details»
(PDF) RORγt inhibitors as potential back-ups for the
Nov 17, 2016 · Recently Vitae Pharmaceuticals (to be acquired by Allergan) reported positive top-line results from a Phase 2a clinical trial of RORγt inhibitor VTP-43742 in psoriatic patients.See details»
Vitae制药(VTAE)股票股价_股价行情_财报_数据报告 - 雪球
Mar 17, 2016 · 简介：Vitae Pharmaceuticals,Inc.于2001年5月在特拉华州成立。 该公司是一家临床阶段的生物技术公司，专注于发现和开发代表有重大的未满足的，市场机会大的疾病医疗需 …See details»
Vitae Pharmaceuticals LLC (Vitae Pharmaceuticals LLC) - 药物管线_ …
VTP-50469 is a potent, orally available, small molecule inhibitor of the MLL-menin interaction with pM binding affinity for menin. Therefore, it was of interest to test the in vivo efficacy of VTP …See details»